EEX gets new members as more over-the-counter trading comes on board
The exchange recorded 37% year-on-year growth in volumes of its flagship European power futures in January, which had grown 63% across 2024, CEO Peter Reitz said in an interview with Reuters.
"There are two drivers: new members and more over-the-counter (OTC) market volumes shifting to the exchange," Reitz said.
He said that the volatility of wind and solar electricity production was creating short-term supply risks, and thus hedging needs, also noting increasing digitisation resulting in algorithmic trading.
Some 60 companies joined the EEX in 2024 to make a total of 950.
Reitz heads the 25-year-old wholesale trading platform which contributes 10% to the turnover of its parent Deutsche Boerse (DB1Gn.DE), opens new tab. He said EEX will widen its lead over the over-the-counter business.
"There is a move to the Deutsche Boerse (DB1Gn.DE), opens new tab clearing house, away from uncleared brokerage trades...I see the shift continuing," Reitz said.
The EEX increased its market share in German power futures to 85% in 2024 on the exchange from 81% a year earlier, with the remainder OTC, he said.
Since the 2008 financial crisis, OTC customers have been turning more to regulated marketplaces to comply with European Union financial rules, reduce counterparty risks, and try to save money on fees bundled across products and regions.
EEX will offer new "Mon-Sun Peak Power Futures" in Spain later this month to account for southern Europe's rising solar generation, Reitz said.
EEX overall electricity trading volumes rose 43% last year to 12,371 terawatt hours (TWh). January volume was up 37% at 1,188 TWh.
Asked for a volume forecast for 2025, Reitz declined, pointing to hard-to-gauge geopolitical risks and varying energy mixes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
European shares end flat as healthcare stocks weigh after Trump's tariff threat
Aug 6 (Reuters) - European shares closed flat on Wednesday, surrendering early session gains, as healthcare stocks felt the pinch from U.S. President Donald Trump's latest threat to impose higher tariffs on pharmaceutical imports. The pan-European STOXX 600 (.STOXX), opens new tab index closed 0.06% lower, breaking its two-day winning streak despite starting the session on a positive note. Healthcare stocks bore the brunt of the selling pressure. The sector index (.SXDP), opens new tab plunged 2.8% to its lowest level in more than three months after Trump unveiled a graduated tariff plan targeting pharmaceutical imports that could see levies on the sector jump up to 250% within 18 months. "This is where it's important to be specific about tariffs because certain stocks and sectors will be impacted differently across regions," said Steve Sosnick, chief market analyst at Interactive Brokers. "In Europe and Asia, investors are considering tariff impacts more carefully since exporters bear much of the brunt directly." The sector was also singed as Novo Nordisk ( opens new tab warned it expects continued competition from copycat versions of its Wegovy obesity drug this year, a message that sent shares of the Danish drug maker down 5.4%. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since then. Meanwhile, Swiss President Karin Keller-Sutter met with U.S. Secretary of State Marco Rubio to discuss potential trade solutions after Trump announced a 39% tariff on Swiss goods. The talks focused on increasing Swiss purchases of U.S. energy and defence products to avert the steep tariff, which threatens significant damage to Switzerland's export-driven economy. Switzerland's benchmark SMI index (.SSMI), opens new tab fell 0.9%, weighed down by drugmakers Novartis (NOVN.S), opens new tab and Roche (ROG.S), opens new tab which lost 3.3% and 2.6%, respectively. Bayer ( opens new tab shares tumbled 9.9% on investor concerns that the German pharmaceutical firm's earnings were inflated by soccer player transfer fees rather than supported by its core healthcare and agriculture businesses. On the data front, Euro zone retail sales grew quicker than thought in June, reinforcing views that the 27-nation bloc remains resilient to trade uncertainty. Among others, Beiersdorf ( opens new tab fell 8.4% and was among top decliners after the German consumer goods maker cut its annual organic sales growth outlook. On the flip side, Siemens Energy ( opens new tab rose 1% after the company said it expects to hit the upper end of its 2025 growth outlook estimates. Hiscox (HSX.L), opens new tab was the top gainer on the index, gaining 9.4% after reporting a rise in first-half insurance premiums supported by its retail business growth.
Reuters
2 hours ago
- Reuters
Charles River profit forecast clouded by order cancellations from biotechs
Aug 6 (Reuters) - Charles River Laboratories' (CRL.N), opens new tab annual profit forecast raise on Wednesday was clouded by investor concerns about the higher number of order cancellations from clients, sending the contract research firm's shares down 8% in afternoon trading. The company's quarterly book-to-bill ratio – the number of orders versus those fulfilled – came in at 0.82x. Evercore ISI analyst Elizabeth Anderson said the ratio was below Wall Street expectations of 0.94x, adding some questions remain about demand environment in the sector. Charles River CEO Jim Foster said on a conference call that while proposals were higher in the quarter, cancellations from biotechs were also higher. Contract research organizations – including Charles River, Fortrea (FTRE.O), opens new tab and ICON (ICLR.O), opens new tab – have posted better-than-expected quarterly profit, reflecting a rebound in spending from pharmaceutical and biotech clients after a cautious stretch driven by tighter sector financing. Charles River's Foster, however, said that funding for smaller biotechs is still more cash constrained, due to the funding slowdown, and mid-sized biotechs are performing better, as many can support their R&D programs without external funding. "We are continuing to see clear signs that the biopharmaceutical demand is stabilizing, and in this environment, we are making gradual progress to return to organic revenue growth," he added. The Wilmington, Massachusetts-based company raised its 2025 adjusted profit forecast to $9.90 to $10.30 per share, from its previous range of $9.30 to $9.80. Charles River's overall second-quarter revenue came in at $1.03 billion, surpassing analysts' estimate of $985.1 million, according to data compiled by LSEG. On an adjusted basis, quarterly profit was $3.12 per share, above estimates of $2.50.
Belfast Telegraph
3 hours ago
- Belfast Telegraph
Co Down countryside bungalow with easy access to Belfast on the market for £525,000
It's a bright bungalow that extends to approximately 2,200 sq ft and offers four bedrooms and three reception rooms, with a flexible option to enjoy five bedrooms and two reception spaces. Watch: Stunning four-bed property in Dromore on the market for £525,000 Number 32's reception hall has a vaulted ceiling and large format Italian marble effect tiles and steps down to the sitting area. Double doors lead to the kitchen and sliding doors provide access to the rear deck. There is a study/TV room with walnut effect flooring and the living room has a corner window with ceramic 'rustic plank' effect tiled floor. The kitchen has space for a dining table and chairs and features an extensive range of dove grey, high-gloss, hand-painted German cupboards with high and low-level units. Amenities include Nordmende double ovens, a four-ring ceramic hob, worktop lighting and French doors to the deck. The utility room is plumbed for a washing machine and has a range of high and low cupboards. One bedroom, with corner window and pale grey oak laminate flooring, has an en suite wet room with floating basin and Mira Vie shower. A second bedroom has an en suite shower room — facility only, buyer to complete to personal choice. There are an additional two bedrooms, both with herringbone pattern grey oak flooring and a facility for a walk-in wardrobe. The family bathroom has a feature egg-shaped bath with mixer taps, floating vanity unit, a corner shower and recessed lighting. Externally, there is a pebble driveway and turning space, plus easily managed gardens to front, side and rear with lawns, fencing and hedges. There's also a sheltered, recessed circular patio and barbecue area. Despite its rural setting, the property is just 15 minutes from Royal Hillsborough and 30 minutes from Belfast. Offers over £525,000. For more information contact Rodgers & Browne on 028 9042 1414.
